Pharmacokinetics of intraperitoneal mitomycin C

Area of Science:

• Oncology
• Pharmacokinetics
• Chemotherapy

Background:

• Intraperitoneal chemotherapy with mitomycin C (MMC) offers favorable pharmacokinetics but poses systemic exposure risks.
• Quantifying MMC exposure via plasma concentration-time profiles (AUC) is crucial for safety and efficacy.
• Current dosing strategies may not achieve maximal tolerated doses, potentially limiting therapeutic outcomes.

Purpose of the Study:

• To determine the optimal dosing strategy for intraperitoneal mitomycin C (MMC) in chemotherapy perfusion.
• To balance high regional drug exposure (AUCperfusate) with acceptable systemic toxicity (AUCplasma).
• To establish a reliable and rational dosing method for intraperitoneal MMC administration.

Main Methods:

• Analysis of pharmacokinetic data, including plasma concentration-time profiles (AUC) and systemic exposure.
• Evaluation of toxicity, specifically grade III/IV leucopenia, in patients receiving intraperitoneal MMC.
• Comparison of body surface area (BSA)-based dosing versus fixed concentration dosing.
• Assessment of MMC administration in three divided doses versus single administration.

Main Results:

• AUCplasma following intraperitoneal MMC was approximately half that of intravenous administration.
• Grade III/IV leucopenia occurred in 28% of patients, considered transient and acceptable.
• Dosing based on body surface area (BSA) demonstrated reliability and low inter-individual variation.
• Administering MMC in three divided doses promotes more equal exposure of peritoneal structures.

Conclusions:

• Body surface area (BSA)-based dosing in three divided administrations is recommended for intraperitoneal MMC chemotherapy.
• This method ensures rational and reliable dosing, optimizing regional exposure while managing systemic toxicity.
• Standardization of perfusion techniques is essential for accurate pharmacokinetic comparisons and dose optimization.